
How to balance remote participation with site-based assessments, clinical oversight and reliable evidence in medical device trials.
Hybrid clinical trials offer opportunities to make study participation more flexible without removing the clinical oversight that medical device investigations often require.
But not every trial activity is suited to a remote approach.
Medical device studies frequently involve hands-on procedures, imaging, technical assessments, investigator training, and specialist oversight. These activities may require participants to attend a clinical site.
Other activities, such as certain follow-up assessments, patient-reported outcomes, and routine consultations, may be conducted remotely when appropriate.
The challenge is determining which approach best supports the study.
More flexibility does not always mean less complexity.
Moving activities away from clinical sites can reduce travel and participation burden. However, it can also introduce challenges around data consistency, technology access, participant support, and coordination between study teams.
A hybrid model that appears more convenient for patients may create additional demands for investigators and sites.
These considerations need to be assessed alongside the study's clinical and regulatory objectives.
Several questions become important:
- Which assessments require direct clinical oversight?
- Where could remote participation meaningfully reduce patient burden?
- How might different settings affect data quality and consistency?
- What additional responsibilities could a hybrid model create for sites and participants?
The answers will vary depending on the device, patient population, study endpoints, and intended evidence.
For some investigations, remote follow-up may offer meaningful advantages. For others, maintaining more activities at clinical sites may provide greater consistency and control.
Neither approach is inherently better.
Hybrid trial design requires balancing participant accessibility with operational feasibility and the quality of evidence being generated.
These decisions are most valuable when considered early, rather than introducing remote elements after the study design has already been established.
A well-designed hybrid trial is not necessarily one with more decentralised activities.
It is one where each activity takes place in the setting best suited to its purpose.
The goal is not to make a trial as remote as possible, but to make it as effective and practical as possible.
